MetaVia (formerly NeuroBo Pharmaceuticals) is a clinical-stage cardiometabolic biotech with two lead programs licensed from Korean partner Dong-A ST: DA-1726, a once-weekly subcutaneous oxyntomodulin analog acting as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for obesity and MASH; and vanoglipel (DA-1241), a first-in-class GPR119 agonist for MASH and type 2 diabetes.
DA-1726's Phase 1 MAD trial in 2026 documented compelling weight loss with best-in-class potential for glucose control, waist reduction, and tolerability. The 48 mg higher-dose Phase 1 cohort data landed at EASL 2026 Day 1 (May 27, 2026 Barcelona) with safety, tolerability, pharmacokinetics, and exploratory noninvasive liver assessment. The 16-week Phase 1 Part 3 titration study delivers full data in Q4 2026. Vanoglipel posted positive Phase 2a MASH data at AASLD November 2025, with the DPP-4 inhibitor combination arm outperforming monotherapy on HbA1c and liver inflammation. The three MetaVia ADA 2026 late-breaking abstracts (June 7 New Orleans) extend the DA-1726 and vanoglipel data sets.
Stories here cover MetaVia trial readouts, regulatory milestones, and the broader cardiometabolic peptide landscape. See #da-1726, #vanoglipel, and #gpr119 for adjacent threads.
MetaVia's higher-dose Phase 1 readout for DA-1726 at EASL 2026 produced specific efficacy numbers: the 48 mg cohort in obese but otherwise healthy adults achieved 9.1% mean body-weight reduction and a 9.8 cm waist-circumference reduction at Day 54, with exploratory FibroScan liver improvements and no serious adverse events. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog acting as a 3:1 ratio GLP-1/glucagon dual receptor agonist for obesity and MASH. The 9.1% weight loss in roughly eight weeks is a fast trajectory for an early-phase obesity peptide and supports MetaVia's case heading into the 16-week Phase 1 Part 3 titration study reading out Q4 2026. The waist reduction (a glucagon-receptor-driven visceral-fat signal) and the FibroScan liver improvements position DA-1726 in the dual obesity-and-MASH lane alongside survodutide and pemvidutide. MetaVia's three ADA 2026 late-breaking abstracts (June 7 New Orleans) extend the DA-1726 and vanoglipel data sets.
MetaVia presented late-breaking Phase 1 data on DA-1726 at the EASL Congress 2026 today in Barcelona. The poster titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment' covers the 48 mg dose level. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for obesity and MASH. The 4-week Phase 1 MAD trial earlier in 2026 documented compelling weight loss with best-in-class potential glucose control (GLP-1R arm), waist reduction (GCGR arm), and tolerability profile. The current 16-week Phase 1 Part 3 titration study is designed to optimize higher-dose levels and tolerability with full data expected Q4 2026. The EASL poster extends the early-phase MASH biomarker package and supports the planned Phase 2 advancement.
MetaVia confirmed Monday May 18 that three late-breaking abstracts have been accepted at the ADA 2026 Scientific Sessions (June 5-8 New Orleans). DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1R/GCGR dual agonist for obesity and MASH; Phase 1 Part 3 higher-dose titration results will be presented, with full Phase 1 trial data expected in Q4 2026. Vanoglipel (DA-1241) is a first-in-class GPR119 agonist that promotes endogenous release of GLP-1, GIP, and PYY from the gut; the ADA poster covers synergistic preclinical effects in combination with resmetirom (Madrigal's MASH therapy) and with metformin for type 2 diabetes. The three-poster slate positions MetaVia as one of several mid-cap obesity-pipeline names with clinical data inflections clustered into the ADA + ASCO + EASD 2026 calendar.
MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.